Wednesday, July 30, 2025

Leadership Change at Novo Nordisk: Maziar Mike Doustdar Appointed New CEO

Leadership transition at Novo Nordisk: Effective August 7, 2025, Maziar Mike Doustdar will take over as President and CEO of the Danish pharmaceutical company. He succeeds Lars Fruergaard Jørgensen, who steps down after more than three decades with the company.

Doustdar, currently Executive Vice President of International Operations, has a remarkable track record: under his leadership, international sales more than doubled to approximately DKK 112 billion in 2024. With nearly 20,000 employees across more than 80 countries, he has significantly shaped Novo Nordisk’s global business.

"Mike is an exceptional leader with a clear vision," said Helge Lund, Chair of Novo Nordisk. "He has the unanimous support of the Board and will lead Novo Nordisk into its next phase of growth."

Mike Doustdar commented on his appointment: “It’s a tremendous privilege to lead this company at a time of great opportunity and change. I bring a strong performance mindset and clear focus on innovation.”

In parallel with the CEO transition, structural changes are underway: the former EVP areas Research & Early Development and Development will be merged under the leadership of Martin Holst Lange, who will also assume the role of Chief Scientific Officer (CSO).

Marcus Schindler, the current CSO, will retire following a transition period. He is recognized for his scientific leadership and contributions.

Emil Kongshøj Larsen will succeed Doustdar as EVP of International Operations. He brings extensive leadership experience from Europe, Africa, the Middle East, and strategic roles in Commercial Affairs.

The new Executive Management structure takes effect on August 7, 2025, positioning Novo Nordisk to meet future challenges and opportunities in the global healthcare market.